Hepatitis C virus inhibitors

US10617675B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• David B. Frennesson · Naugatuck, US
• Piyasena Hewawasam · Middletown, US
• Omar D. Lopez · Wallingford, US
• Van N. Nguyen · West Haven, US
• Mark G. Saulnier · Haddam, US
• Yong Tu · Cheshire, US
• Alan Xiangdong Wang · Guilford, US
• Gan Wang · Wallingford, US
• Ningning Xu · Lawrenceville, US
• Roshan Yadavrao Nimje · Bengaluru, IN
• Hasibur Rahaman · Bengaluru, IN
• Samayamunthula Venkata Satya Arun Kumar Gupta · Bengaluru, IN
• Nicholas A. Meanwell · East Hampton, US
• Makonen Belema · North Haven, US

Key dates

• Filing date: Jul 27, 2016
• Grant date: Apr 14, 2020
• Expiry date: Jul 27, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2300/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.